These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 16638734)

  • 1. Pharmacokinetics of buspirone in autistic children.
    Edwards DJ; Chugani DC; Chugani HT; Chehab J; Malian M; Aranda JV
    J Clin Pharmacol; 2006 May; 46(5):508-14. PubMed ID: 16638734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and CNS pharmacodynamics of the 5-HT1A agonist buspirone in humans following acute L-tryptophan depletion challenge.
    Jagannathan V; Venitz J
    Methods Find Exp Clin Pharmacol; 1997 Jun; 19(5):351-62. PubMed ID: 9379784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral buspirone causes a shift in the dose-response curve between the elevated-plus maze and Vogel conflict tests in Long-Evans rats: relation of brain levels of buspirone and 1-PP to anxiolytic action.
    Vaidya AH; Rosenthal DI; Lang W; Crooke JJ; Benjamin D; Ilyin SE; Reitz AB
    Methods Find Exp Clin Pharmacol; 2005 May; 27(4):245-55. PubMed ID: 16082425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug.
    Mahmood I; Sahajwalla C
    Clin Pharmacokinet; 1999 Apr; 36(4):277-87. PubMed ID: 10320950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics, brain uptake, and receptor binding of tandospirone and its metabolite 1-(2-pyrimidinyl)-piperazine.
    Miller LG; Thompson ML; Byrnes JJ; Greenblatt DJ; Shemer A
    J Clin Psychopharmacol; 1992 Oct; 12(5):341-5. PubMed ID: 1362206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats.
    Zuideveld KP; Rusiç-Pavletiç J; Maas HJ; Peletier LA; Van der Graaf PH; Danhof M
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1130-7. PubMed ID: 12438536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone.
    Lamberg TS; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 1998 Jun; 63(6):640-5. PubMed ID: 9663178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and tolerability of buspirone during oral administration to children and adolescents with anxiety disorder and normal healthy adults.
    Salazar DE; Frackiewicz EJ; Dockens R; Kollia G; Fulmor IE; Tigel PD; Uderman HD; Shiovitz TM; Sramek JJ; Cutler NR
    J Clin Pharmacol; 2001 Dec; 41(12):1351-8. PubMed ID: 11762563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of a newly identified active metabolite of buspirone after administration of buspirone over its therapeutic dose range.
    Dockens RC; Salazar DE; Fulmor IE; Wehling M; Arnold ME; Croop R
    J Clin Pharmacol; 2006 Nov; 46(11):1308-12. PubMed ID: 17050795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buspirone plasma concentrations.
    Barbanoj MJ; Parra P; Jané F
    Clin Pharmacol Ther; 1998 Sep; 64(3):347-8. PubMed ID: 9757159
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacokinetics of buspirone following oral administration to rhesus monkeys.
    Marathe PH; Shen F; Markham P; Greene DS
    J Pharm Pharmacol; 1999 May; 51(5):601-7. PubMed ID: 10411220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of buspirone extended-release tablets: a single-dose study.
    Sakr A; Andheria M
    J Clin Pharmacol; 2001 Jul; 41(7):783-9. PubMed ID: 11452712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses.
    Barbhaiya RH; Shukla UA; Pfeffer M; Pittman KA; Shrotriya R; Laroudie C; Gammans RE
    Eur J Clin Pharmacol; 1994; 46(1):41-7. PubMed ID: 7911763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain targeting studies on buspirone hydrochloride after intranasal administration of mucoadhesive formulation in rats.
    Khan S; Patil K; Yeole P; Gaikwad R
    J Pharm Pharmacol; 2009 May; 61(5):669-75. PubMed ID: 19406007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of buspirone and 1-(2-pyrimidinyl)-piperazine (1-PP) in human plasma by capillary gas chromatography.
    Kivistö KT; Laitila J; Mårtensson K; Neuvonen PJ
    Ther Drug Monit; 1999 Jun; 21(3):317-21. PubMed ID: 10365644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone.
    Laine K; Ahokoski O; Huupponen R; Hänninen J; Palovaara S; Ruuskanen J; Björklund H; Anttila M; Rouru J
    Eur J Clin Pharmacol; 2003 Dec; 59(10):761-6. PubMed ID: 14566442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative multidose pharmacokinetic study of buspirone extended-release tablets with a reference immediate-release product.
    Sakr A; Andheria M
    J Clin Pharmacol; 2001 Aug; 41(8):886-94. PubMed ID: 11504277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of pharmacokinetic interaction between buspirone and haloperidol in patients with schizophrenia.
    Huang HF; Jann MW; Wei FC; Chang TP; Chen JS; Juang DJ; Lin SK; Lam YW; Chien CP; Chang WH
    J Clin Pharmacol; 1996 Oct; 36(10):963-9. PubMed ID: 8930784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous determination of buspirone, gepirone, ipsapirone and their common metabolite 1-(2-pyrimidinyl)piperazine in rat plasma and brain by high-performance liquid chromatography.
    Bianchi G; Caccia S
    J Chromatogr; 1988 Oct; 431(2):477-80. PubMed ID: 2907515
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical pharmacokinetics of oral buspirone in patients with impaired renal function.
    Caccia S; Vigano GL; Mingardi G; Garattini S; Gammans RE; Placchi M; Mayol RF; Pfeffer M
    Clin Pharmacokinet; 1988 Mar; 14(3):171-7. PubMed ID: 3370902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.